Natco Pharma
Drug Manufacturers - Specialty & Generic · NATCOPHARM
Mid CapHealthcareHigh Growth
V.C. Nannapaneni
Chairman & Managing Director · Visionary
Company DNA
Founder-Centric
About
Natco Pharma is a Mid Cap company in the Healthcare sector, listed on NSE as NATCOPHARM. With a market cap of ₹18K Cr and revenue of ₹4K Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Disruptor approach to innovation, the company operates at a Startup-Speed pace. Strong promoter-led governance with the CMD deeply involved in R&D and strategic direction for over three decades. Its strategic mandate: The company needs to leverage its strong R&D capabilities to scale niche oncology and complex generic portfolios in highly regulated markets.
FAQ
What kind of company is Natco Pharma?
Natco Pharma is a Mid Cap Healthcare company (NATCOPHARM) in the High Growth phase with a market cap of ₹18K Cr. It is classified as Founder-Centric in culture.
What is Natco Pharma's culture and work environment like?
Natco Pharma has a Founder-Centric culture with Disruptor innovation DNA and a Startup-Speed pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Strong promoter-led governance with the CMD deeply involved in R&D and strategic direction for over three decades.
Who leads Natco Pharma?
Natco Pharma is led by V.C. Nannapaneni (Chairman & Managing Director), a Visionary leader with 59 years of experience.
What are Natco Pharma's financials?
Natco Pharma reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 32.3%. Operating margin: 44.9%. Market cap: ₹18K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationDisruptor
PaceStartup-Speed
PurposeMission-First
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
Strong promoter-led governance with the CMD deeply involved in R&D and strategic direction for over three decades.
Mandate
The company needs to leverage its strong R&D capabilities to scale niche oncology and complex generic portfolios in highly regulated markets.
The company needs to leverage its strong R&D capabilities to scale niche oncology and complex generic portfolios in highly regulated markets.
Financials
Revenue FY25₹4K Cr
PAT FY25₹2K Cr
Rev CAGR 5Y32.3%
OPM44.9%
NPM42.7%
ROE24.8%
ROCE25.8%
P/E11
Fwd P/E24.7
P/B2
D/E3
Mkt Cap₹18K Cr
Promoter51.1%
Institutional12.5%
Similar Culture
Could You Lead Natco Pharma?
Take the Genome Benchmark →